PFO ACCESS Registry
Expanded access is currently available for this treatment.
Verified January 2015 by St. Jude Medical
Information provided by (Responsible Party):
St. Jude Medical
First received: December 21, 2007
Last updated: January 30, 2015
Last verified: January 2015
Closure of Patent Foramen Ovale with the AMPLATZER® PFO OCCLUDER in patients with at least two cryptogenic strokes due to presumed paradoxical embolism through a patent foramen ovale and who have failed conventional therapy.
Patent Foramen Ovale
Device: Device closure with the AMPLATZER PFO Occluder
|Genders Eligible for Study:
- Patent foramen ovale-(PFO)
- recurrent stroke
- failed antiplatelet/anticoagulant therapy
- International normalized ration (INR) outside of 2-3 intracardiac thrombus (subjects may be enrolled after resolution of thrombus)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00583401
St. Jude Medical
No publications provided
||St. Jude Medical
History of Changes
|Other Study ID Numbers:
|Study First Received:
||December 21, 2007
||January 30, 2015
||United States: Food and Drug Administration
Keywords provided by St. Jude Medical:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on March 26, 2015
Foramen Ovale, Patent
Heart Defects, Congenital
Heart Septal Defects
Heart Septal Defects, Atrial